Panacea Biotec Intrinsic Value
Panacea Biotec intrinsic value. Panacea Biotec (PANACEABIO) median intrinsic value is ₹105.08 from 7 valuation models (range ₹105–₹876), vs current price ₹350.25 — -70.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Read PANACEABIO ex-dividend dates for the complete payout history and dividend yield track record.
PANACEABIO Valuation Methods Summary — DCF, Graham Number & P/E
Panacea Biotec intrinsic value across 7 models vs current price ₹350.25 — upside/downside and value range per method. Compare with PANACEABIO fundamental valuation to assess whether the stock is under or overvalued.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹105.08 | ₹84.06 - ₹126.10 | -70.0% | EPS: ₹0.32, Sector P/E: 22x |
| Book Value Method | asset | ₹875.62 | ₹788.06 - ₹963.18 | +150.0% | Book Value/Share: ₹1381.67, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹700.50 | ₹630.45 - ₹770.55 | +100.0% | Revenue/Share: ₹1146.67, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹533.33 | ₹480.00 - ₹586.66 | +52.3% | EBITDA: ₹32.00Cr, EV/EBITDA: 10x |
| PEG Ratio Method | growth | ₹105.08 | ₹94.57 - ₹115.59 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹105.08 | ₹94.57 - ₹115.59 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹105.08 | ₹94.57 - ₹115.59 | -70.0% | EPS: ₹0.32, BVPS: ₹1381.67 |
PANACEABIO Intrinsic Value vs Market Price — All Valuation Models
Panacea Biotec fair value range ₹105–₹876 vs current market price ₹350.25 across 7 valuation models. For current market price and key ratios, visit Panacea Biotec share price screener.
PANACEABIO Intrinsic Value Analysis — Undervalued or Overvalued?
Panacea Biotec median intrinsic value ₹105.08, current price ₹350.25 — Trading Above Calculated Value by 70.0%, margin of safety -100.0%.
What is the intrinsic value of PANACEABIO?
Based on our comprehensive analysis using 7 different valuation methods, the estimated intrinsic value of Panacea Biotec (PANACEABIO) is ₹105.08 (median value). With the current market price of ₹350.25, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹105.08 to ₹875.62, indicating ₹105.08 - ₹875.62.
Is PANACEABIO undervalued or overvalued?
Based on our multi-method analysis, Panacea Biotec (PANACEABIO) appears to be trading above calculated value by approximately 70.0%.
PANACEABIO Financial Health — Key Ratios vs Industry Benchmarks
Panacea Biotec financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 6.04 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | -0.5% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 2.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.55x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
PANACEABIO Cash Flow Quality — Operating & Free Cash Flow
Panacea Biotec operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹17 Cr | ₹-4 Cr | Positive Operating Cash Flow | 6/10 |
| March 2025 | ₹-27 Cr | ₹-27 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-423 Cr | ₹-423 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-108 Cr | ₹-108 Cr | Negative Cash Flow | 3/10 |